Detalhe da pesquisa
1.
Safety and activity of RRx-001 in patients with advanced cancer: a first-in-human, open-label, dose-escalation phase 1 study.
Lancet Oncol
; 16(9): 1133-1142, 2015 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-26296952